On January 5, 2026, Cytokinetics Executive Vice President Andrew Callos executed a sale of 15,000 CYTK shares, reducing his total holdings to 50,440 shares. This transaction follows two December sales reported in SEC filings: 1,042 shares on December 8 and 52,486 shares on December 5. Collectively, Callos’s December and January sales generated proceeds of approximately 3.46 million dollars. Investors will note the concentrated timing and scale of these dispositions by a senior executive, which may signal a shift in insider sentiment or portfolio rebalancing ahead of key clinical and regulatory milestones.

Cytokinetics President and Chief Executive Officer Robert I. Blum is scheduled to deliver a presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026 at 9:45 AM Pacific Time. The presentation will cover progress with MYQORZO (aficamten), the company’s FDA-approved treatment for symptomatic obstructive hypertrophic cardiomyopathy, and recent positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use recommending EU marketing authorization. Mr. Blum will also outline the pipeline of cardiac muscle dysfunction therapies, including aficamten’s non-obstructive HCM study, the investigational heart failure treatment omecamtiv mecarbil, and ulacamten for preserved ejection fraction. A live webcast will be available via the Cytokinetics Investors & Media website, with replay archived for 90 days.